Navigation Links
Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
Date:3/5/2008

IRVINE, Calif., March 5 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), the world leader in the science of heart valves, today announced the first three human implants of the next-generation Edwards transcatheter aortic heart valve, performed by John Webb, M.D., director of the cath lab and cardiac intervention at St. Paul's Hospital in Vancouver, British Columbia.

"Edwards is proud to extend our leadership in this transformational technology with this important development in our transcatheter heart valve program," said Larry L. Wood, Edwards' corporate vice president, transcatheter valve replacement. "We expect to initiate a clinical trial of this new valve in Europe before the end of the year."

Edwards' next-generation balloon-expandable pericardial tissue valve features a cobalt chromium alloy frame that reduces the profile by four to five French. This enables easier access into and within the patient's vasculature for delivery of the valve without open-heart surgery. The new valve will also be offered in additional sizes and builds upon Edwards' more than 20 years of clinical experience and innovation with the most advanced tissue engineering technologies.

"This is a very exciting milestone in the progression of minimally-invasive valve therapy. The refinements to the new Edwards valve provide the opportunity to make the transcatheter technology available to an even broader group of patients suffering from severe aortic stenosis," said Webb, who along with his multidisciplinary team has performed more than 150 transcatheter aortic valve replacement procedures. "Providing patients and clinicians with a comprehensive selection of treatment options, including this new valve, can increase the lik
'/>"/>

SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Edwards Lifesciences Announces Organizational Changes
2. Edwards Lifesciences to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008
4. Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve
5. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
6. Edwards Lifesciences Forecasts Strong Growth in 2008
7. Marshall Edwards, Inc. to Present at BIO Investor Forum 2007
8. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
9. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
10. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
11. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
Post Your Comments:
*Name:
*Comment:
*Email: